Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease